GlaxoSmithKline Pharmaceuticals Stock: Balance Sheet and Debt
GLAXO.NSGlaxoSmithKline Pharmaceuticals has a debt to equity ratio of 0.01 and an interest coverage of over 100x.
Daily figure as of 22 Nov 2026
Balance Sheet Over Time
In all 10 fiscal years since 2017 GlaxoSmithKline Pharmaceuticals held more cash than debt.
Total Assets and Equity Ratio
How large the balance sheet of GlaxoSmithKline Pharmaceuticals Limited is, how much of it is equity and how much is goodwill from acquisitions.
Equity ratio
Figures as a table
| Year | Total assets | Goodwill and intangible assets | of which goodwill | Equity ratio | Net debt |
|---|---|---|---|---|---|
| 2007 | $193.05M | $454.86K | $454.86K | 67.3% | −$3.26M |
| 2008 | $219.7M | $4.55M | $4.55M | 67.8% | −$16.1M |
| 2009 | $250.39M | $4.55M | $4.55M | 67.9% | −$103.23M |
| 2010 | $269.52M | not reported separately | not reported separately | 71.5% | −$186.51M |
| 2011 | $303.26M | not reported separately | not reported separately | 69.4% | −$215.56M |
| 2012 | $330.81M | $4.55M | $4.55M | 63.1% | −$219.92M |
| 2013 | $333.25M | not reported separately | not reported separately | 65.0% | −$220.6M |
| 2014 | $337.69M | not reported separately | not reported separately | 63.6% | −$217.74M |
| 2015 | $347.93M | not reported separately | not reported separately | 75.8% | −$210.64M |
| 2016 | $328.68M | not reported separately | not reported separately | 55.7% | −$142.46M |
| 2017 | $324.13M | $3.48M | not split out | 66.8% | −$97.82M |
| 2018 | $425.95M | $7.84M | not split out | 52.1% | −$136.94M |
| 2019 | $422.05M | $7.07M | not split out | 54.7% | −$123.79M |
| 2020 | $338.34M | $5.35M | not split out | 58.1% | −$110.06M |
| 2021 | $335.94M | $4.68M | not split out | 48.1% | −$121.75M |
| 2022 | $499.95M | $3.72M | not split out | 57.5% | −$311.05M |
| 2023 | $358.95M | $3.68M | not split out | 52.3% | −$176.81M |
| 2024 | $383.77M | $2.54M | not split out | 50.0% | −$198.34M |
| 2025 | $443.28M | $1.44M | not split out | 47.5% | −$268.48M |
| 2026 | $466.56M | $707.45K | not split out | 52.4% | −$293.83M |
The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.
Equity and Debt
What the Company Owns and Owes
- Cash & equivalents
- Equity
- Debt
Figures as a table
| Year | Cash & equivalents | Equity | Debt | Debt / Equity |
|---|---|---|---|---|
| 2007 | $3.86M | $130M | $601.9K | 0 |
| 2008 | $16.72M | $149M | $628.53K | 0 |
| 2009 | $103.24M | $170.01M | $2.56K | 0 |
| 2010 | $187.09M | $192.73M | $586.11K | 0 |
| 2011 | $216.12M | $210.58M | $556.99K | 0 |
| 2012 | $220.45M | $208.87M | $529.29K | 0 |
| 2013 | $221.1M | $216.54M | $495.63K | 0 |
| 2014 | $218.19M | $214.7M | $446.98K | 0 |
| 2015 | $210.98M | $263.73M | $336.17K | 0 |
| 2016 | $142.72M | $183.01M | $256.06K | 0 |
| 2017 | $97.99M | $216.55M | $172.11K | 0 |
| 2018 | $137.05M | $221.99M | $106.72K | 0 |
| 2019 | $123.85M | $230.9M | $62.91K | 0 |
| 2020 | $114.58M | $196.45M | $4.51M | 0.02 |
| 2021 | $125.48M | $159.51M | $3.74M | 0.02 |
| 2022 | $313.22M | $287.34M | $2.17M | 0.01 |
| 2023 | $178.49M | $187.89M | $1.68M | 0.01 |
| 2024 | $200.36M | $191.81M | $2.01M | 0.01 |
| 2025 | $269.55M | $210.55M | $1.07M | 0.01 |
| 2026 | $297.42M | $244.66M | $3.59M | 0.01 |
Debt of Industry Peers
GlaxoSmithKline Pharmaceuticals's debt to equity is lower than that of 65 of 79 other stocks in the Healthcare sector.
| Stock | Debt to equity | Equity ratio |
|---|---|---|
| Daiichi Sankyo | 0.18 | 41.6% |
| Orion | 0.24 | 63.9% |
| Zhangzhou Pientzehuang Pharmaceutical. | 0.07 | 85.9% |
| CSPC Pharmaceutical Group | 0.02 | 74.0% |
| Grifols | 1.26 | 38.6% |
| Ono Pharmaceutical | 0.14 | 77.4% |
| GlaxoSmithKline Pharmaceuticals | 0.01 | 52.4% |
| Organon | 11.70 | 5.8% |
| Virbac | 0.26 | 58.8% |
Figures from the latest fiscal year. The eight peers closest in market value, largest first.
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Strong since 7 Nov 2026; valuation signal Overvalued since 22 Nov 2026
- Price: closing price of 20 Nov 2026
- Amounts in US dollars at the ECB reference rate of 20 Nov 2026 ($1 = ₹92.6752)
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2026. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
